文献速递产科母胎医学

游离DNA非整倍体筛查时代的绒毛膜绒毛取样:谨慎的选择标准可最大化筛查与侵入性检测的临床效用

Chorionic villus sampling in the cell-free DNA aneuploidy screening era: careful selection criteria can maximise the clinical utility of screening and invasive testing.
PubMed 文献 · Prenat Diagn · 2017-03-12

该回顾性队列研究分析了2008年8月至2015年2月澳大利亚墨尔本两家机构共2051例单胎妊娠绒毛膜绒毛取样(CVS),发现引入游离DNA(cfDNA)筛查后CVS率从9.8%降至3.9%,每例CVS检出致病性染色体异常的比例从12.9%升至25.2%,其中21三体占致病性结果的比例从52%升至70%;16例(5.3%)致病性异常无法被当前cfDNA检测预测。

要点

  • 引入cfDNA筛查后CVS率从9.8%降至3.9%,每例CVS致病性染色体异常检出率从12.9%升至25.2%。
  • 致病性结果中21三体占比从52%升至70%,16例(5.3%)致病性异常无法被当前cfDNA检测预测。
  • 若无胎儿结构异常、颈项透明层增厚或相关家族史,cfDNA筛查未检出致病性染色体异常的风险较低。

核心结论

  • cfDNA筛查对常见非整倍体筛查性能的提升与分子核型分析诊断效用的增加之间存在日益凸显的矛盾。
  • 若无胎儿结构异常、颈项透明层增厚或相关家族史,提供cfDNA筛查时未检出致病性染色体异常的风险较低。

研究设计与样本

  • 回顾性队列研究,纳入2008年8月至2015年2月在澳大利亚墨尔本皇家妇女医院(The Royal Women's Hospital, Melbourne)和Women's Ultrasound Melbourne因任何指征对单胎妊娠实施的全部CVS操作。
  • 共完成2051例CVS、25373例12周超声扫描和2394例cfDNA检测。
  • 核型按致病性及标准cfDNA筛查面板的可检测性进行分类。

主要发现

  • 引入cfDNA筛查后,每例12周超声扫描对应的CVS率从9.8%降至3.9%。
  • 每例CVS检出的致病性染色体异常比例从12.9%升至25.2%。
  • 致病性结果中21三体占比从52%升至70%。
  • 16例(5.3%)CVS检出的致病性染色体异常无法被当前cfDNA检测预测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To quantify the impact of cell-free DNA (cfDNA) screening on chorionic villus sampling (CVS) test indications and outcomes in a tertiary maternity service. METHODS: Retrospective cohort study of all CVS procedures performed for any indication on singleton pregnancies at The Royal Women's Hospital, Melbourne, and at Women's Ultrasound Melbourne, Australia, between August 2008 and February 2015. Karyotypes were classified according to pathogenicity and detectability by standard cfDNA screening panels. RESULTS: A total of 2051 CVS procedures, 25 373 twelve-week scans and 2394 cfDNA tests were performed. The CVS rate per 12-week scan fell from 9.8 to 3.9% following introduction of cfDNA screening. The yield of pathogenic chromosomal anomalies per CVS increased from 12.9 to 25.2%, with 70% of pathogenic results now comprising T21, up from 52%. Sixteen (5.3%) of the pathogenic chromosomal abnormalities identified on CVS would not have been predicted by current cfDNA tests. CONCLUSIONS: There is an evolving tension between improved screening performance for common aneuploidies offered by cfDNA testing, and the increasing diagnostic utility of molecular karyotyping. However, the risk of not identifying pathogenic chromosomal abnormalities is low if cfDNA screening is offered in the absence of a structural fetal anomaly, increased nuchal translucency or relevant family history. © 2017 John Wiley & Sons, Ltd.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Kane SC, Reidy KL, Norris F, et al. Chorionic villus sampling in the cell-free DNA aneuploidy screening era: careful selection criteria can maximise the clinical utility of screening and invasive testing. Prenat Diagn. 2017. PMID: 28207933. doi:10.1002/pd.5026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。